A 28-year-old woman with moderate persistent asthma is switched from beclomethasone (twice daily) to fluticasone (once daily). Which clinical feature would best explain the advantage of fluticasone over beclomethasone in this patient?

Explanation

## Clinical Advantage of Fluticasone Over Beclomethasone: Depot Effect and Compliance ### The Depot Phenomenon **Key Point:** Fluticasone's high lipophilicity creates a depot effect in lung tissue, allowing once-daily dosing with sustained 24-hour anti-inflammatory coverage, whereas beclomethasone requires twice-daily dosing to maintain therapeutic effect. ### Mechanism of Sustained Action ```mermaid flowchart TD A[Inhaled Fluticasone]:::action --> B[High lipophilicity]:::outcome B --> C[Partitions into lung surfactant<br/>and epithelial tissue]:::action C --> D[Forms local depot]:::outcome D --> E[Slow dissociation over<br/>12-24 hours]:::action E --> F[Sustained receptor occupancy<br/>and anti-inflammatory effect]:::outcome F --> G[Once-daily dosing sufficient]:::action G --> H[Improved compliance<br/>and steady-state control]:::outcome I[Inhaled Beclomethasone]:::action --> J[Moderate lipophilicity]:::outcome J --> K[Shorter lung tissue retention<br/>4-6 hours]:::action K --> L[Twice-daily dosing required]:::outcome L --> M[Risk of missed doses<br/>and suboptimal control]:::urgent ``` ### Comparison: Dosing Schedule Impact on Asthma Control | Parameter | Fluticasone (Once Daily) | Beclomethasone (Twice Daily) | | --- | --- | --- | | Lung tissue residence time | 12–24 hours | 4–6 hours | | Plasma half-life | 7–8 hours | 2–3 hours | | Dosing frequency | Once daily (morning) | Twice daily (morning + evening) | | Compliance burden | Lower | Higher | | Steady-state coverage | Continuous | Interrupted between doses | | Risk of control loss | Minimal (single missed dose) | Higher (missed evening dose = 18-hour gap) | ### Clinical Pearl **High-Yield:** In asthma management, once-daily ICS therapy (fluticasone, mometasone, ciclesonide) significantly improves patient compliance compared to twice-daily regimens, leading to better long-term asthma control and reduced exacerbation rates [cite:Harrison 21e Ch 305]. ### Why Compliance Matters in Asthma Asthma is a chronic inflammatory disease requiring continuous anti-inflammatory therapy. Missed doses allow: 1. Rapid re-accumulation of inflammatory mediators 2. Loss of airway protection against triggers 3. Increased risk of acute exacerbations 4. Suboptimal lung function over time Once-daily fluticasone reduces the cognitive burden and improves adherence, especially in young adults who may have irregular daily schedules. **Mnemonic:** **DEPOT** = Depot Effect Prolongs Ongoing Therapy - **D**epot formation in lung tissue - **E**xtended duration (12–24 hours) - **P**rolonged anti-inflammatory effect - **O**nce-daily dosing possible - **T**herapy compliance improved